P3 Health Partners (NASDAQ:PIII) versus 20/20 Biolabs (NASDAQ:AIDX) Critical Survey

P3 Health Partners (NASDAQ:PIII) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Profitability

This table compares P3 Health Partners and 20/20 Biolabs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
P3 Health Partners	-6.55%	N/A	-16.40%
20/20 Biolabs	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for P3 Health Partners and 20/20 Biolabs, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
P3 Health Partners	1	2	1	0	2.00
20/20 Biolabs	1	0	1	0	2.00

P3 Health Partners presently has a consensus price target of $17.00, indicating a potential upside of 317.69%. 20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 1,698.56%. Given 20/20 Biolabs’ higher probable upside, analysts clearly believe 20/20 Biolabs is more favorable than P3 Health Partners.

Institutional & Insider Ownership

7.7% of P3 Health Partners shares are held by institutional investors. 10.9% of P3 Health Partners shares are held by insiders. Comparatively, 29.8% of 20/20 Biolabs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares P3 Health Partners and 20/20 Biolabs”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
P3 Health Partners	$1.46 billion	0.02	-$147.95 million	($33.00)	-0.12
20/20 Biolabs	$2.04 million	1.74	-$3.74 million	($0.54)	-0.51

20/20 Biolabs has lower revenue, but higher earnings than P3 Health Partners. 20/20 Biolabs is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Summary

20/20 Biolabs beats P3 Health Partners on 7 of the 10 factors compared between the two stocks.

About P3 Health Partners

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.

About 20/20 Biolabs

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD.